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Abstract
Spinocerebellar ataxias are dominantly inherited neurodegenerative disorders with no disease-modifying treatment. We
previously identified the selective serotonin reuptake inhibitor citalopram as a safe and effective drug to be repurposed for
Machado-Joseph disease. Pre-symptomatic treatment of transgenic (CMVMJD135) mice strikingly ameliorated mutant
ataxin-3 (ATXN3) pathogenesis. Here, we asked whether citalopram treatment initiated at a post-symptomatic age would
still show efficacy. We used a cohort of CMVMJD135 mice that shows increased phenotypic severity and faster disease
progression (CMVMJD135hi) compared to the mice used in the first trial. Groups of hemizygous CMVMJD135hi mice
were orally treated with citalopram. Behavior, protein analysis, and pathology assessment were performed blindly to
treatment. Our results show that even when initiated after symptom onset, treatment of CMVMJD135hi mice with
citalopram ameliorated motor coordination and balance, attenuating disease progression, albeit to a lesser extent than that
seen with pre-symptomatic treatment initiation. There was no impact on ATXN3 aggregation, which contrasts with the
robust reduction in ATXN3-positive inclusions observed in CMVMJD135 mice, when treated pre-symptomatically. Post-
symptomatic treatment of CMVMJD135hi mice revealed, however, a limited neuroprotective effect by showing a tenden-
cy to repair cerebellar calbindin staining, and to increase the number of motor neurons and of NeuN-positive cells in
certain brain regions. While supporting that early initiation of treatment with citalopram leads to a marked increase in
efficacy, these results strengthen our previous observation that modulation of serotonergic signaling by citalopram is a
promising therapeutic approach for Machado-Joseph disease even after symptom onset.
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Introduction
Machado-Joseph disease (MJD) or spinocerebellar ataxia
type 3 is a clinically heterogeneous neurodegenerative dis-
ease [1, 2], caused by an expansion of a cytosine-adenine-
guanine (CAG) repeat tract in the ATXN3 gene, which en-
codes for an abnormally long polyglutamine (polyQ) seg-
ment in the ataxin-3 protein (ATXN3) [3]. The symptoms
of MJD reflect the involvement of multiple neurological
systems, which include ataxia, diplopia, dysphagia,
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dysarthria, and ophthalmoplegia, as well as fasciculations,
amyotrophy, dystonia, and/or spasticity [4, 5]. This disor-
der is characterized by a widespread neuronal degeneration
affecting several regions of the central nervous system,
such as the cerebellum, brainstem, basal ganglia, and spi-
nal cord [6]. No effective disease-modifying treatment is
currently available for MJD.
Citalopram is a safe, well-tolerated antidepressant that be-
longs to the group of the selective serotonin reuptake inhibi-
tors (SSRIs) [7, 8]. These compounds share the same cellular
target, the serotonin (5-HT) transporter (SERT), which is re-
sponsible for 5-HT uptake into serotonergic neurons [9].
While the exact mechanism of action of SSRIs has yet to be
elucidated, these compounds may exert their antidepressant
activity by inhibiting SERTand increasing extracellular levels
of 5-HT [10].
Antidepressants are often prescribed to patients with neu-
rodegenerative diseases to treat depression and anxiety symp-
toms [11]. Interestingly, several antidepressants have also
shown neuroprotective effects in vitro, as well as in animal
models of Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease, or spinal and bulbar muscular atrophy
[12–19].
We previously described an in vivo repurposing screen of
1200 FDA-approved small molecules and identified chemical
suppressors of mutant ATXN3-induced neurotoxicity in
Caenorhabditis elegans [20]. Through this unbiased ap-
proach, we found that citalopram and other SSRIs reduced
mutant ATXN3 aggregation in C. elegans and restored its
motor capacity. In this simple animal model, early initiation
and prolonged treatment with citalopram resulted in increased
therapeutic efficacy. Chronic citalopram treatment of
CMVMJD135 mice [22], a vertebrate model of MJD, when
initiated at a pre-symptomatic age, strikingly ameliorated their
motor coordination impairments, reducing mutant ATXN3
aggregation and neuronal loss [20]. These results suggest that
small-molecule modulation of serotonergic signaling in pre-
symptomatic stages may represent a promising therapeutic
approach for MJD.
To mimic the most frequent clinical situation of symptom-
driven diagnosis and treatment of MJD patients, here, we
asked whether citalopram treatment would still be effective
to ameliorate mutant ATXN3-mediated pathogenesis if initi-
ated after motor symptom installation in MJD mice.
Our results showed that, indeed, post-symptomatic
citalopram treatment ameliorated loss of balance and motor
coordination, attenuating disease progression in a cohort of
MJD mice of increased disease severity (CMVMJD135hi).
These results suggest that 5-HT recapture inhibition can be
used as a disease-modifying therapy for MJD and perhaps
other conformational disorders, even when initiated after
symptom onset, but also support increased efficacy of early
treatment initiation.
Materials and Methods
Ethics Statement
All animal procedures were conducted in accordance with
European regulations (European Union Directive 2010/63/
EU). Animal facilities and the persons directly involved in
animal experimentation (SE, SD-S, SO, AT-C) were certified
by the Portuguese regulatory entity—Direcção Geral de
Alimentação e Veterinária. All the protocols were approved
by the Animal Ethics Committee of the Life and Health
Sciences Research Institute, University of Minho. All experi-
ments were designed with commitment to the principles of
refinement, reduction, and replacement and performed ac-
cording to FELASA guidelines to minimize discomfort,
stress, and pain to the animals, with defined humane endpoints
(20% reduction of the body weight, inability to reach food and
water, presence of wounds in the body, and dehydration) [23].
The status of specified pathogens of sentinel animals, main-
tained in the same animal room, was monitored throughout the
study.
Transgenic Mouse Model and Drug Administration
CMVMJD135hi mice (background C57BL/6) were generated
as previously described [22], but by selecting progenitor ani-
mals with a mean CAG repeat size of 138 ± 5 [± standard
deviation (SD)]. Animals were housed in a conventional ani-
mal facility at weaning, in groups of five animals, in filter-
topped polysulfone cages 267 × 207 × 140 mm (370 cm2 floor
area) (Tecniplast, Buguggiate, Italy), using corncob bedding
(Scobis Due, Mucedola SRL, Settimo Milanese, Italy). All
animals were maintained under standard laboratory condi-
tions: an artificial 12-h light/dark cycle (lights on from 8 am
to 8 pm), with 21 ± 1 °C of room temperature and a relative
humidity of 50–60%. Mice were fed with a standard diet
(4RF25 during the gestation and postnatal periods, and
4RF21 after weaning; Mucedola SRL, Settimo Milanese,
Italy) and water ad libitum. DNA extraction, animal genotyp-
ing, and CAG repeat size analyses were performed as previ-
ously described [24]. Themean CAG repeat size [± SD] for all
transgenic mice used in this study, the CMVMJD135hi ani-
mals, was of 138 ± 5, distributed evenly among treatments
(CMVMJD135hi 138 ± 6 and CMVMJD135hi cit 137 ± 5).
Age-matched WT littermate animals were used as controls.
Male mice were used in this study. The first symptom that
appears in CMVMJD135 mice is loss of motor strength in
the hanging wire test using an inverted grid, which is already
installed at 6 weeks of age, followed by the appearance of
motor uncoordination deficits [22]. To verify installation of
motor symptoms in CMVMJD135hi mice, we evaluated bal-
ance and motor coordination of the mice on the balance beam
walk and motor swimming paradigms [25]. Transgenic
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animals showed increased latency time to reach the safe plat-
forms in both behavioral tests when compared to WTanimals
at 10 weeks of age. Therefore, treatment was initiated at
11 weeks of age. We administrated citalopram hydrobromide
(CAS 59729-32-7, kindly provided by H. Lundbeck A/S,
Denmark) in the drinking water at a dosage of 8 mg/kg.
Citalopram-supplemented water was changed three times per
week throughout the entire duration of the trial to ensure drug
activity. The trial was terminated at 28 weeks of age, when
most of the vehicle-treated transgenic animals could not com-
plete any of the motor tests (e.g., balance beam walk test,
motor swimming test, and footprints).
Experimental Design
ARRIVE guidelines were followed throughout the study [26].
Experimental design was based on power analyses for optimi-
zation of sample size, as described previously [20]. Mouse
sample size calculations were previously performed for each
behavioral test and pathological analyses, assuming a power
of 0.95 and 0.8, respectively, and a significance level of
p < 0.05 [20]. Transgenic and non-transgenic drug- and
placebo-treated animals were alternately housed and assigned
to treatment. All behavioral experiments and neuropathologi-
cal analyses were conducted by researchers who were blind to
genotype and treatment.We used groups of 13–16 animals per
genotype/treatment for behavioral tests and groups of four to
six animals for quantification of ATXN3 intranuclear inclu-
sions, assessment of astrogliosis, cell counts, andWestern blot
analyses. Regarding genotype-phenotype correlations, data
obtained in the previous preclinical trial using vehicle-
treated CMVMJD135 mice [20] was used for correlation anal-
yses in conjugation with data from the CMVMJD135hi mice
(present study). Motor performance in the balance beam walk
and motor swimming tests were analyzed at 26 weeks of age
for all animals (n = 27) and correlated to their CAG repeat
number.
Behavioral Assessment
Behavioral assessment was performed during the diurnal pe-
riod, with five males per cage, including CMVMJD135hi
hemizygous transgenic mice and WT littermates (n = 15–16
per genotype) treated with citalopram or with vehicle (water).
Body weight was registered throughout the study. All behav-
ioral tests started in a symptomatic stage (10 weeks) and were
conducted until 26 or 28 weeks of age. Neurological testing
included (1) a selection of tests from the SHIRPA protocol,
namely assessment of tremors, gait quality, and limb clasping
[27, 28]; (2) footprinting analysis and stride length quantifica-
tion; (3) balance beam walk (12-mm and 27-mm square
beams); and (4) motor swimming tests. All behavioral tests
were performed as previously described [20, 22, 24]. Briefly,
tremors assessment was performed while the animals were in
a viewing jar and scored (as absent,mild (discontinuous trem-
or), or severe (continuous tremor)) while animals were immo-
bile.Gait qualitywas assessed by the experimenter in an open
arena (55 × 33 × 18 cm). Freely moving animals were scored
as normal, abnormal (incorrect posture of the body and tail,
with decreased distance over the ground), and limited (very
limited movement). To determine limb clasping, animals were
picked up by the tail and slowly descending towards a hori-
zontal surface. Mice were observed and scored as absent (ex-
tension of the hindlimbs),mild (contraction observed in one of
the limbs), or severe (contraction observed in both limbs). To
register footprint patterns, the fore and hind paws of the ani-
mals were coated with non-toxic red and black inks, respec-
tively. Animals were allowed to walk along a 100 cm long ×
4.2 cm width × 10 cm height inclined runway (a clean paper
sheet was used for each mouse) in the direction of an enclosed
safe black box. Stride length was obtained by measuring the
distance between two paw prints. Three values were obtained
in six consecutive steps and the mean of the three values was
used. The same consecutive steps were used to evaluate the
severity of foot dragging. Mice were scored as absent/mild =
0 (up to three steps), mild = 1 (more than three steps out of
six), and severe = 2 (all steps out of six). Balance beam walk
test comprised 3 days of training (three trials per animal) in the
12-mm square beam, and, in the fourth day, animals were
tested in the 12-mm and/or in the 27-mm square beam (two
trials per animal were recorded). If the animal turned around
or fell from the beam, the trial was considered invalid. Each
animal is allowed to fail twice. The time the animals took to
cross the beams was recorded, and if animals stopped, this
time was discounted. The percentage of therapeutic efficacy
was calculated taking the mean latency time to reach the safe
platform in the beam walk test of transgenic mice and
subtracting the mean latency time of WT mice in each pre-
clinical trial, to obtain a reference value. This value
corresponded to 100% of therapeutic efficacy in that trial
(i.e., assuming that the best possible drug will make the trans-
genic animals behave likeWT). The difference between laten-
cy time of vehicle-treated transgenic mice and latency time of
cit-treated mouse of the same trial, relative to the value of
100% efficacy, corresponded to the percentage of therapeutic
effect. This was calculated at 26 weeks of age both in the pre-
[20] and post-symptomatic trials (this study). In the motor
swimming test, mice were trained for two consecutive days
(animals were allowed three trials) to cross a transparent acryl-
ic water tank (100 cm long) to a safe (black acrylic-made)
platform at the end. The latency to cross this tank was regis-
tered from a 60-cm distance (the initiation position was
marked with a blue line). The water temperature was main-
tained at 23 °C using a thermostat. Animals were tested for
three consecutive days (two trials per animal) and the latency
to cross the tank assessed by the experimenter.
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Immunohistochemistry and Quantification
of Neuronal Inclusions
Twenty-eight-week-old WT and CMVMJD135hi littermate
mice, vehicle- and citalopram-treated (n = 4–6 per group),
were deeply anesthetized [a mixture of ketamine hydrochlo-
ride (150 mg/kg) plus medetomidine (0.3 mg/kg)] and
transcardially perfused with phosphate-buffered saline (PBS)
followed by 4% paraformaldehyde (PFA) (Panreac, USA).
Brains were removed and postfixed overnight in PFA and
either embedded in paraffin or transferred to a 30% sucrose
solution for vibratome processing. Spinal cord tissues were
postfixed overnight in PFA and transferred to a 30% sucrose
solution for vibratome processing. Brain slices (4-μm-thick
paraffin sections or 40-μm-thick vibratome sections) and spi-
nal cord vibratome sections (50-μm-thick) were subjected to
antigen retrieval and then incubated with mouse anti-ATXN3
(1H9) (1:750 for paraffin and 1:500 for vibratome sections,
MAB5360, Millipore), rabbit anti-GFAP (1:500, Dako
Corporation), goat anti-choline acetyltransferase (ChAT,
1:500, AB144P, Millipore), mouse anti-neuronal nuclei
(NeuN, 1:100, MAB377, Millipore), and rabbit anti-
calbindin D-28K (1:1000, AB1778, Millipore) antibodies,
which were detected by incubation with a biotinylated anti-
polyvalent antibody, followed by detection through biotin-
streptavidin coupled to horseradish peroxidase and reaction
with the DAB (3,3′-diaminobenzidine) substrate (Lab
Vision™ Ultra-Vision™ Detection kit, Thermo Scientific or
VECTASTAIN® El i t e® ABC-HRP Ki t , Vec to r
Laboratories). Brain and spinal cord sections were counter-
stained with hematoxylin 25% following standard procedures.
Quantification of ATXN3-positive inclusions was performed
in the pontine nuclei (PN), reticulotegmental nucleus of the
pons (RtTg), facial motor nuclei (7N), lateral reticular nuclei
(LRt), vestibular nuclei (VN), deep cerebellar nuclei (DCN),
and lumbar spinal cord (LSC). Number of GFAP-positive
cells was determined in the substantia nigra (SN) and of
calbindin-positive cells in the Purkinje cells of the cerebellar
cortex (PJc CBX). Counts of ChAT-positive cells were con-
ducted in the LSC, 7N, and dorsal striatum (DS).
Quantification of NeuN-positive neurons was performed in
the PN, DCN, and VN. All quantifications were carried out
in either vehicle- or citalopram-treated animals (n = 4 for each
condition, 4 slices per animal) and normalized to total area and
to WT- or transgenic-vehicle controls using an Olympus
BX51 stereological microscope (Olympus, Japan) and the
Visiopharm integrator system software (Visopharm,
Denmark) as previously described [24].
Immunoblotting Analysis
Protein isolation from mouse brainstem, cerebellum, and spi-
nal cord tissue and Western blotting were performed as
previously described [24]. Briefly, the blots were incubated
overnight at 4 °C with the primary antibodies mouse anti-
ATXN3 (1H9) (1:2000, MAB5360, Millipore) and mouse
anti-tubulin (1:5000, T5168, Sigma). Mouse ATXN3 and tu-
bulin were used as loading controls. Antibody affinity was
detected by chemiluminescence, and Western blot quantifica-
tions were performed using Chemidoc XRS Software with
ImageLab Software (Bio-Rad), following the manufacturer’s
instructions.
Statistical Analysis
Normality of variance assumptions was evaluated with
Kolmogorov-Smirnov (K-S) or Shapiro-Wilk (S-W) test (cho-
sen according to n value of each experiment), absolute value
of skewness, kurtosis, and Z-score. Substantial departure from
normality was considered when K-S or S-W test showed
P < 0.05, absolute value of skewness > 2, absolute value of
kurtosis > 7 and Z-score > 1.9 [29]. Continuous variables with
normal distributions and with homogeneity of variance (eval-
uated by Levene’s test) were analyzed with repeated-measures
two-way ANOVA for longitudinal multiple comparisons,
using genotype and treatment as factors. One-way ANOVA
was used for paired comparisons, using Tukey test for post
hoc comparisons. Variables lacking homogeneity of variances
were analyzed with parametric tests using Welch’s correction
(and Games-Howell was used for post hoc comparisons).
Other variables were analyzed through non-parametric
Mann-Whitney U test or Kruskal-Wallis H test for two or
more groups, respectively. Genotype-phenotype correlations
were analyzed using Pearson correlation coefficient
(GraphPad). All statistical analyses were performed using
SPSS 22.0 (SPSS Inc., Chicago, IL) and G-Power 3.1.9.2
(University Kiel, Germany). A critical value for significance
of P < 0.05 was used throughout the study. Crosses (×) repre-
sent CMVMJD135 and CMVMJD135hi comparisons, aster-
isks (*) represent WT and CMVMJD135hi comparisons, am-
persands (&) represent WT versus WT cit comparisons, and
number s igns (# ) represent CMVMJD135hi and
CMVMJD135hi cit comparisons.
Results
Establishment of a Cohort of CMVMJD135 Mice
with a More Severe Phenotype
To determine the efficacy of post-symptomatic citalopram treat-
ment in an animal model of disease with increased pathogenic-
ity, we used a transgenic mouse model of MJD, the
CMVMJD135, replicating patients’ symptomatology by
displaying progressive motor dysfunction and selective neuro-
pathology [22]. As seen in MJD patients [30], the mean CAG
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repeat number in the CMVMJD135 mice correlates inversely
with the age at onset of symptoms and directly with symptom
severity and disease progression. This feature can be used to
generate subsets of animals with distinct degrees of disease se-
verity and progression rates. In this study, we chose to increase
the mean CAG repeat length of the original CMVMJD135
mice, used in our previous study with citalopram [20], by 10
repeats (CMVMJD135hi). The increase in mean CAG repeat
size from 128 in CMVMJD135 mice (CMVMJD135 vehicle
group of our previous study) to 138 in CMVMJD135hi mice
caused a significant aggravation of the motor uncoordination
and loss of balance, as measured by the motor swimming and
balance beam walk behavior paradigms (Fig. 1b, c).
CMVMJD135hi mice also showed an accelerated rate of dis-
ease progression (ANOVA repeated measures, P = 0.042 for
motor swimming and P < 0.0001 for balance beam tests).
Latency time in both behavioral tasks significantly correlated
with the CAG repeat length of the two groups (Pearson
correlation coefficient r2 = 0.4037 (n = 27) and r2 = 0.6315
(n = 22), respectively; P < 0.001) at 26 weeks of age (Fig. 1d,
e). Age at onset of symptoms was significantly anticipated in
CMVMJD135hi mice, by four or more weeks to a maximum of
16 weeks for stride length evaluation (Supplementary Table 1).
Symptomatic Citalopram Treatment of CMVMJD135hi
Mice Ameliorated Gait Quality
At 10 weeks of age, CMVMJD135hi mice showed significant
impairments in motor coordination and balance compared to
WT animals (Supplementary Fig. 1). Oral chronic administra-
tion of citalopram (8 mg/kg) or drinking water to
CMVMJD135hi mice and toWT non-transgenic littermate con-
trols was initiated at 11 weeks of age (study design shown in
Fig. 2a). Assessment of mouse body weight throughout the
duration of the trial (until 28 weeks of age; Fig. 2b) revealed
no changes caused by citalopram treatment. Whereas some
Fig. 1 CMVMJD135hi mice present increased phenotype severity
related to higher (CAG)n repeat length. a CAG repeat number
comparison between two independent mouse groups, the one used
previously in the pre-symptomatic citalopram preclinical trial
(CMVMJD135) and CMVMJD135hi mice (present study) (n = 27).
Significant differences were observed between CMVMJD135 and
CMVMJD135hi mouse groups (treated with vehicle) in preclinical trials
regarding their performance in the b motor swimming test and in the c
balance beam walk test (12-mm square). Genotype versus phenotype
correlation for the d motor swimming test (CMVMJD135 +
CMVMJD135hi, n = 27) and e 12-mm square balance beam walk
(CMVMJD135 + CMVMJD135hi, n = 22) at 26 weeks of age. Open
circles refer to CMVMJD135 group and closed circles refer to
CMVMJD135hi group. Data are presented as mean ± SD (a) or mean ±
SEM (b, c), xP < 0.05, xxP < 0.01, and xxxP < 0.001 (Student’s t test,
repeated-measures two-way ANOVA, Tukey correction, and Pearson
correlation coefficient). r2 square of the Pearson correlation coefficient
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neurological symptoms of CMVMJD135hi mice, like body
tremors, showed only marginal improvements upon citalopram
treatment (Fig. 2c), limb clasping and gait quality scores were
restored until 26 weeks of age (Fig. 2d, e). In agreement with
what was observed when citalopram was administrated before
the onset of motor symptoms, treated CMVMJD135hi mice still
displayed dragging of the paws (Supplementary Fig. 2); how-
ever, the stride length was significantly ameliorated at 20 weeks
of age (Fig. 2f) in this trial, even though no changes were ob-
served beyond this time point.
Fig. 2 Chronic post-symptomatic citalopram treatment ameliorated gait
quality of CMVMJD135hi mice. a Schematic representation of the
preclinical therapeutic trial design. b Body weight, c tremors, d limb
clasping, e gait quality, and f footprint stride length were evaluated until
28 weeks of age in WT and CMVMJD135hi vehicle- and citalopram-
treated mice (WT, n = 13; WT cit, n = 17; CMVMJD135hi, n = 16;
CMVMJD135hi cit, n = 15). Mild improvements were observed for
tremors, clasping, gait quality, and stride length, while no effect was
observed in body weight upon treatment. Data are presented as mean ±
SEM; *P < 0.05, **P < 0.01, and ***P < 0.001. Asterisks (*) indicate
statistical significance between WT and CMVMJD135hi mice; the
ampersands and number signs indicate statistical significance between
WT and WT cit and between CMVMJD135hi and CMVMJD135hi cit
mice, respectively. WT mice show no signs of tremors, altered limb
clasping, or gait quality and are not represented in c, d, and e for
simplicity (repeated-measures two-way ANOVA, one-way ANOVA,
Tukey correction, and Mann Whitney U test for non-continuous
variables). The red arrow indicates age of treatment initiation at
11 weeks. cit citalopram
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Post-symptomatic Treatment with Citalopram
Improves Motor Coordination and Balance
in CMVMJD135hi Mice
Vehicle-treated CMVMJD135hi mice showed severe motor
coordination and balance defects, which precluded testing of
citalopram’s beneficial effects at advanced stages of disease
progression, as by 26 weeks, 40% of the animals were unable
to cross the balance beam. Nevertheless, upon citalopram
treatment, we observed a significant amelioration in motor
performance in the different beam sizes analyzed, until
26 weeks of age (Fig. 3a, b). The animals that did not perform
the test (40%) at 26 weeks had amean CAG repeat size of 140
± 6 [± standard deviation (SD)] whereas the animals that were
able to cross the beam (60%) had a mean CAG repeat size of
136 ± 4, being this difference statistically significant
(Student’s t test, P = 0.04). However, among the mice that
completed the task, citalopram-treated mice with a higher
CAG repeat length did not take more time to traverse the
beam, which suggests a disease-modifying effect for
citalopram, being the slope of the correlation curve between
CAG repeat length and latency to fall lower (Supplementary
Fig. 3). In the motor swimming test, citalopram-treated
CMVMJD135hi mice took less time to reach the safe platform
(Fig. 3c), although not reaching statistical significance.
Overall, these results demonstrate that post-symptomatic
citalopram treatment can still reduce the impairment in motor
coordination and delay disease progression ofMJD transgenic
mice, although to a lesser extent than when the treatment is
initiated before the onset of motor symptoms.
Post-symptomatic Treatment with Citalopram
Confers a Limited Neuroprotective Effect
to CMVMJD135hi Mice
The analysis of brain tissue of post-symptomatic citalopram-
treated CMVMJD135hi mice suggested that the positive im-
pact on animals’ behavior may be accounted by the limited
neuroprotective effects exerted by the SSRI, even when ad-
ministrated after symptom installation. Concerning mutant
protein aggregation, and in contrast with pre-symptomatic
treatment, the number of ATXN3 intranuclear inclusions in
several areas of the brainstem and in the ventral horn of the
lumbar spinal cord did not change when treatment was initi-
ated at symptomatic ages (Fig. 4a and Supplementary Fig. 4a).
Fig. 3 Citalopram post-symptomatic treatment improves balance and
coordination of CMVMJD135hi mice. a Significant differences were
observed in the 12-mm square balance beam walk (curve comparison
over time P < 0.001, 14–26 weeks) and in the b 27-mm square beam
(P < 0.01, 26 weeks). At 26 weeks, data is shown for only 60% of the
CMVMJD135hi vehicle-treated animals, since the other 40% were
unable to complete this test. c In the motor swimming test, transgenic
treated mice (CMVMJD135hi cit, n = 15) took slightly less time to cross
the swimming pool than vehicle-treated mice (CMVMJD135hi, n = 16)
(curve comparison over time P > 0.05, 10–28 weeks). Data are presented
as mean ± SEM, *P < 0.05, **P < 0.01, and ***P < 0.001. The asterisks
(*) indicate statistical significance between WT and CMVMJD135hi
mice; the number signs indicate statistical significance between
CMVMJD135hi and CMVMJD135hi cit mice (repeated-measures two-
way ANOVA and one-way ANOVA, Tukey correction). The red arrow
indicates age of treatment initiation at 11 weeks
b
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Fig. 4 Impact of post-symptomatic citalopram treatment of
CMVMJD135hi mice on brain ATXN3 intranuclear inclusions and
protein levels. a ATXN3-positive inclusions in the pontine nuclei (PN),
lumbar spinal cord (LSC), and deep cerebellar nuclei (DCN) of vehicle-
and citalopram-treated CMVMJD135hi mice (n = 4, 28 weeks). b
Brainstem (BS), spinal cord (SC), and cerebellum (CB) immunoblots
and quantification of total human ATXN3 protein from vehicle- and
citalopram-treated CMVMJD135hi mice (n = 4, 28 weeks). Data are
presented as mean ± SEM, normalized to WT, P> 0.05, Student’s t test,
Levene correction for SC data. Scale bars = 10 μm (PN and LSC) and
20 μm (DCN). cit citalopram, WT wild-type, PN pontine nuclei, LSC
lumbar spinal cord, DCN deep cerebellar nuclei, BS brainstem, SC spinal
cord, CB cerebellum
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There was, however, a tendency towards reduction of ATXN3
aggregation in the deep cerebellar nuclei (DCN) of
CMVMJD135hi mice (P = 0.071) (Fig. 4a). As seen for pre-
symptomatic treatment of CMVMJD135 mice [20], total
levels of ATXN3 protein did not change significantly upon
post-symptomatic treatment of CMVMJD135hi mice in the
brainstem (BS), spinal cord (SC), and cerebellum (CB)
(Fig. 4b and Supplementary Fig. 5).
Post-symptomatic treatment of CMVMJD135hi mice
with citalopram failed to attenuate reactive astrogliosis
in the substantia nigra (SN) (Fig. 5a). Moreover,
citalopram treatment exerted limited neuroprotective ef-
fects. In brain regions like the pontine nuclei (PN) of
the brainstem and in the DCN, in which at 28 weeks of
age there is only a scarce neuronal loss, SSRI treatment
led to a tendency of an increase in the number of NeuN-
positive neurons in transgenic mice. At this age, there is
also a trend towards a reduction of ChAT-positive motor
neurons in the spinal cord of transgenic animals, and
citalopram treatment circumvented this neuronal loss to
some extent. The reduction in calbindin D-28K-positive
cells seen in the Purkinje cells of the cerebellar cortex of
CMVMJD135hi mice was also partially prevented by
post-symptomatic citalopram treatment (Fig. 5b and
Supplementary Fig. 4b). These results suggest that, unlike
in early treatment, in which there was a robust suppres-
sion in mutant ATXN3 aggregation, post-symptomatic
citalopram treatment promotes neuronal survival in cer-
tain regions of the mouse brain, in agreement with the
observed phenotypic effects, but has a weak to absent
impact on mutant protein aggregation.
Discussion
In this study, we observed that post-symptomatic treat-
ment of MJD transgenic mice with the SSRI citalopram
attenuated their loss of balance and motor dysfunction,
highlighting the importance of the use of antidepressants
in neurodegenerative diseases beyond the treatment of de-
pressive symptoms.
The t h e r a p e u t i c c ap a c i t y o f c i t a l o p r am in
CMVMJD135hi mice that show increased symptom se-
veri ty and faster progression rates compared to
CMVMJD135 mice [20] further supports the advance-
ment of this drug to clinical trials in MJD patients. As
the disease progresses, however, the ability of citalopram
to prevent aggregation and neuronal loss may not be suf-
ficient to cope with the already installed neurodegenera-
tive process; hence, an early initiation of treatment may
be required. Importantly, the safety profile of SSRIs [31]
allows preventive treatment of mutation carriers as well as
its administration after symptom installation, with
treatment efficacy being reported in two rodent models
of MJD [20, 21]. Our previous results showed that pre-
symptomatic citalopram treatment [20] exerted its effects
mostly in the CNS-related symptoms rather than on the
periphery (e.g., muscular strength). Here, treatment was
initiated after the manifestation of core motor coordina-
tion symptoms, resulting in a percentage of therapeutic
efficacy of 36%, as measured at 26 weeks of age in the
balance beam walk test, in contrast with the 66% obtained
when treatment was initiated before the installation of
motor defects. This may be due to the combination of late
treatment initiation (at 11 versus 5 weeks), reduced treat-
ment duration (17 versus 29 weeks), and increased sever-
ity of the symptoms of CMVMJD135hi mice. Both pre-
and post-symptomatic citalopram preclinical trials result-
ed in preservation and/or an increase in the number of
neuronal cells in affected brain regions of transgenic
mice, corresponding to those affected in MJD patients
but not typically assessed when studying the mechanism
of action of SSRIs in major depressive disorder models
[32].
While citalopram treatment presented a striking effect
in protein aggregation suppression, when initiated before
the appearance of ATXN3 inclusions [20], this was not so
evident when the treatment was initiated post-symptomat-
ically, at an age in which inclusions are already present.
The timing of citalopram treatment initiation appears
therefore to have a differential impact on ATXN3
folding/aggregation suggesting that this drug may modu-
late specific proteostasis subnetwork(s) acting preferen-
tially on the prevention of formation of new aggregates
and/or on the generation of new seeds, and less so by
disaggregating the inclusion bodies already formed.
Interestingly, and regarding the possible mechanism of
action of citalopram in the context of protein aggregation
diseases such as MJD, neurosensory release of 5-HT has
been shown to activate cell non-autonomously the heat
shock factor 1 and downstream molecular chaperones
and to suppress protein misfolding in non-neuronal tissues
of C. elegans [33]. On the other hand, neuronal mitochon-
drial proteotoxic stress induces 5-HT release from seroto-
nergic neurons and activates the unfolded protein re-
sponse of the mitochondria in C. elegans intestine cells
[34]. If a similar mechanism is occurring in vertebrates,
this would be consistent with an aggregation preventive
rather than disruptive mechanism, which is in accordance
with our data. Importantly, pre-symptomatic treatment of
a second MJD transgenic mouse model (YACMJDQ84.2)
[35] with citalopram also resulted in a reduction in
ATXN3 inclusions and abundance, and in the modulation
of certain components of cellular proteostasis, including
restoration of Hsp90beta levels in brains of mice treated
with this drug [21].
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Fig. 5 Assessment of the neuroprotective effects of citalopram post-
s ym p t om a t i c t r e a t m e n t i n CMVMJD1 3 5 h i m i c e . a
Immunohistochemistry and quantification of GFAP-positive cells per
area in substantia nigra (SN) from WT, vehicle- and citalopram-treated
CMVMJD135h i m i c e (n = 5 pe r g r o up , 2 8 week s ) . b
Immunohistochemistry and quantification of NeuN-positive cells per
total area in the pontine (PN) and deep cerebellar nuclei (DCN), ChAT-
positive cells per total area in the lumbar spinal cord (LSC), and calbindin
D-28K-positive Purkinje cells per total area in the cerebellar cortex (PJc
CBX) from WT, vehicle- and citalopram-treated CMVMJD135hi mice
(n = 4 per group, 28 weeks). At least 992 GFAP-positive cells were
counted in the SN; 4973 and 3622 NeuN-positive cells were counted in
the PN and DCN, respectively; 344 ChAT-positive cells were counted in
the LSC, and 4052 calbindin D-28K-positive Purkinje cells were counted
in the PJc CBX, per condition. Data are presented as mean ± SEM,
normalized to WT values, P < 0.05 (one-way ANOVA). Scale bar =
50 μm. cit citalopram, WT wild-type, SN substantia nigra, PN pontine
nuclei, LSC lumbar spinal cord, DCN deep cerebellar nuclei, PJc CBX
Purkinje cells of the cerebellar cortex
Mol Neurobiol
The differential impact of citalopram treatment on
ATXN3 proteotoxicity in the cerebellum, brainstem, and
spinal cord seen in this work and in the study by Ashraf
et al. may reflect the distinct expression pattern/activation
of 5-HT receptors [36–38]; therefore, it would be impor-
tant to identify the specific 5-HT receptors required for
citalopram’s effect on toxicity and aggregation of mutant
ATXN3. Previous studies in C. elegans implicated the
homologs of 5HT1 and 5HT2 receptor families in this
response [20]. Consistently, the antipsychotic aripiprazole
was recently identified in an unbiased screen as a modu-
lator of ATXN3 abundance. Agonism of 5HT1A and an-
tagonism of 5HT2A receptors by aripiprazole may con-
tribute to its therapeutic effect in Machado-Joseph disease
cell and animal models [39].
Our results support a novel use for citalopram in the
treatment of MJD patients. However, the therapeutic ef-
fect found after the installation of core motor symptoms in
mice indicates that early initiation of treatment is prefer-
able, bringing new insight into the design of prospective
clinical trials for this and perhaps other neurodegenerative
diseases.
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